Hregen

Harvardapparatus Regenerative Technology, Inc. (HRGN) is a clinical-stage regenerative medicine company focused on developing innovative therapies for severe esophageal and bronchial diseases. The company has initiated a phase 1 clinical trial to assess the safety and efficacy of its lead products, the Cellspan Esophageal Implant and Cellspan Bronchial Implants. With recent milestones, including FDA approval for its first investigational new drug application and the activation of clinical trial sites, HRGN is transitioning into a clinical-stage company.